258 related articles for article (PubMed ID: 14991117)
1. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Johannsen M; Wilke K; Schnorr D; Loening SA
Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
3. Hormone-refractory prostate cancer: where are we going?
Di Lorenzo G; Autorino R; Figg WD; De Placido S
Drugs; 2007; 67(8):1109-24. PubMed ID: 17521214
[TBL] [Abstract][Full Text] [Related]
4. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
6. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy for prostate cancer].
Itoh N
Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
Rosenberg JE; Small EJ
Clin Prostate Cancer; 2004 Sep; 3(2):122-4. PubMed ID: 15479496
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic options for hormone-refractory prostate cancer].
Miller K; Börgermann C; Thüroff J; Albers P; Wirth M
Urologe A; 2006 May; 45(5):580, 582-5. PubMed ID: 16710677
[TBL] [Abstract][Full Text] [Related]
11. Treatment options in hormone-refractory metastatic prostate carcinoma.
Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of hormone refractory prostate carcinoma].
Wirth MP; Nippgen J
Urologe A; 2003 Nov; 42(11):1453-60. PubMed ID: 14624343
[TBL] [Abstract][Full Text] [Related]
13. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Droz JP; Chaladaj A
BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
[TBL] [Abstract][Full Text] [Related]
14. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Mancuso A; Oudard S; Sternberg CN
Crit Rev Oncol Hematol; 2007 Feb; 61(2):176-85. PubMed ID: 17074501
[TBL] [Abstract][Full Text] [Related]
15. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
16. [Docetaxel for metastatic prostate cancer: early is better].
Gietema JA; Oosting SF
Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
18. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
Autorino R; Di Lorenzo G; Damiano R; De Placido S; D'Armiento M
Urol Int; 2003; 70(1):1-14. PubMed ID: 12566808
[TBL] [Abstract][Full Text] [Related]
19. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
20. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
Oh WK; George DJ; Tay MH
Clin Prostate Cancer; 2005 Jun; 4(1):61-4. PubMed ID: 15992464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
